Sporotrichosis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 77: | Line 77: | ||
| | | | ||
|} | |} | ||
<ref name="pmid17968818">{{cite journal| author=Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America| title=Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 10 | pages= 1255-65 | pmid=17968818 | doi=10.1086/522765 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968818 }} </ref> | <ref name="pmid17968818">{{cite journal| author=Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America| title=Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 10 | pages= 1255-65 | pmid=17968818 | doi=10.1086/522765 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968818 }} </ref> <ref name="pmid21976602">{{cite journal| author=Barros MB, de Almeida Paes R, Schubach AO| title=Sporothrix schenckii and Sporotrichosis. | journal=Clin Microbiol Rev | year= 2011 | volume= 24 | issue= 4 | pages= 633-54 | pmid=21976602 | doi=10.1128/CMR.00007-11 | pmc=PMC3194828 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21976602 }} </ref> | ||
==References== | ==References== |
Revision as of 14:31, 15 January 2016
Sporotrichosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Sporotrichosis medical therapy On the Web |
American Roentgen Ray Society Images of Sporotrichosis medical therapy |
Risk calculators and risk factors for Sporotrichosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]
Treatment
Because spontaneous resolution in cases of sporotrichosis is a rarity, the majority of patients require treatment. The recommended treatment regimens are largely empirical and predominantly based upon retrospective evaluations, case study reports, and nonrandomized control trials.[1] The chart below outlines the effective treatment methods based upon the form of sporotrichosis displayed by an infected human host.
Form | Primary Line of Treatment | Alternative Treatment | Remarks/Other |
---|---|---|---|
Uncomplicated cutaneous |
|
|
Continue treatment for 2-4 weeks after lesions resolve. |
Osteoarticular |
|
|
For a total of 12 months, switch to Itraconazole after resolution/end of treatment. |
Pulmonary |
|
|
Treat less sever cases with a 12 month regimen of Itraconazole. |
Meningeal |
|
|
Precise length of amphotericin B treatment varies. Suppressive treatment with Itraconazole is necessary. |
Dissimated |
|
|
Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with Itraconazole is necessary. |
Sporotrichosis in pregnant women |
|
It is preferable to defer treatment in uncomplicated cases. | |
Sporotrichosis in Children |
|
|
References
- ↑ 1.0 1.1 Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.
- ↑ Barros MB, de Almeida Paes R, Schubach AO (2011). "Sporothrix schenckii and Sporotrichosis". Clin Microbiol Rev. 24 (4): 633–54. doi:10.1128/CMR.00007-11. PMC 3194828. PMID 21976602.